/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
  2. 296: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 2
296: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 2

296: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 2

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders · Oct 15, 2026

Cyclarity's cyclodextrin dimer aims to reverse arterial plaque, navigating unconventional CMC and regulatory pathways for scalable therapy.

Reversing Plaque Shrinks Cardiovascular Trial Size and Duration Compared to Slowing Disease Progression

Traditional cardiovascular trials require tracking thousands of patients across years to measure rare clinical events like heart attacks. Reversing plaque creates a sharper statistical distinction versus control groups than simply slowing growth. This differential may allow drug developers to shorten observation timelines and reduce patient cohort sizes.

296: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 2 thumbnail

296: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 2

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·a month ago

FDA Evaluates Non-Single-Isomer Small Molecules Under Biologic-Like CMC Scrutiny

When synthetic therapies exist as isomeric mixtures lacking single distinct chromatographic peaks, standard small-molecule CMC playbooks fail. Matthew O'Connor notes that regulatory agencies focus heavily on safety and manufacturing consistency, treating isomeric characterization challenges more like a complex biologic than a conventional small molecule.

296: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 2 thumbnail

296: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 2

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·a month ago

Multi-Step Synthetic Dimers Scale Beyond Biologic Equipment Limits at GLP-1 Cost Profiles

Synthetic dimer drugs require multiple synthetic steps and liquid formulations that prevent ultra-cheap generic margins. Even so, Matthew O'Connor emphasizes that production costs remain lower than therapeutic antibodies, enabling massive batch manufacturing without challenging or exceeding standard bioprocessing equipment capacities.

296: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 2 thumbnail

296: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 2

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·a month ago

Clearing Systemic Toxic Metabolites Converts Drug Side Effects Into Multi-Organ Health Benefits

Systemically suppressing specific cell-signaling pathways often produces debilitating off-target toxicity throughout the body. Conversely, therapies designed to eliminate universally toxic metabolites like oxidized cholesterol address root causes of cellular aging, meaning systemic off-target distribution can produce positive therapeutic effects across multiple organs instead of adverse reactions.

296: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 2 thumbnail

296: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 2

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·a month ago

AI-Assisted Non-Invasive Angiography Replaces Invasive Catheters to Enable Pre-Symptomatic Cardiovascular Interventions

Cardiovascular assessment has rapidly transitioned away from invasive catheter angiograms toward non-invasive CT and MRI scans. Combining full-body imaging with artificial intelligence detects microscopic vascular changes before physical symptoms appear, creating a pathway to treat and reverse arterial plaque well before emergency hospitalizations occur.

296: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 2 thumbnail

296: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 2

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·a month ago